EP4497439A1 — Compounds for the treatment or prevention of gout
Assigned to Universitat de les Illes Balears · Expires 2025-01-29 · 1y expired
What this patent protects
The present invention provides compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of a disease or disorder associated with the crystallization of monosodium urate monohydrate, wherein R 1 and R 2 are different and a…
USPTO Abstract
The present invention provides compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of a disease or disorder associated with the crystallization of monosodium urate monohydrate, wherein R 1 and R 2 are different and are selected from -H and -(C 1 -C 6 )alkyl; and R 3 is selected from -H and =O. The invention also provides an in vitro method for eliminating and/or preventing the formation of monosodium urate monohydrate crystals in a composition, and an i n vitro use of a compound of formula (I) for eliminating and/or preventing the formation of monosodium urate monohydrate crystals.
Drugs covered by this patent
- Colcrys (COLCHICINE) · Scilex Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.